Abstract
The expression of programmed cell death-ligand 1 (PD-L1) and its correlation with the prognosis and clinicopathologic features of renal cell carcinoma (RCC) remain controversial to date. Concerning this issue, we had conducted a meta-analysis of relevant studies searched in the Web of Science, PubMed, EMBASE, and Cochrane Library databases. The Newcastle-Ottawa quality assessment scale was applied to assess the quality of the included studies. The hazard ratio (HR) and its corresponding 95% confidence intervals (CIs) were collected by Stata 12.0 and used for the results of overall survival (OS) and disease-free survival (DFS). A total of 1,644 patients in 8 studies were included in this meta-analysis. Results showed that PD-L1 expression significantly correlated with OS (HR = 1.98, 95% CI: 1.22–3.22, Z = 2.77, p = 0.006) and DFS (HR = 3.70, 95% CI: 2.07–6.62, Z = 4.40, p = 0.0001) in ccRCC. Subgroup analysis indicated that PD-L1 expression significantly correlated with the lymph-gland transfer ratio (HR = 2.45, 95% CI: 1.02–5.92, Z = 1.99, p = 0.05) and tumor necrosis (HR = 6.05, 95% CI: 3.78–9.67, Z = 7.51, p < 0.00001). This meta-analysis suggests that PD-L1 expression is a valuable prognostic tool for patients with ccRCC. Subgroup analyses demonstrated that it was helpful for screening patients with RCC who need anti-PD-1/PD-L1 treatment and support them to benefit from such immune-targeted therapy.
References
1.
Torre
LA
, Bray
F
, Siegel
RL
, Ferlay
J
, Lortet-Tieulent
J
, Jemal
A
. Global cancer statistics, 2012
. CA Cancer J Clin
. 2018
;65
(2
):87
–108
. 2.
Ljungberg
B
, Albiges
L
, Abu-Ghanem
Y
, Bensalah
K
, Dabestani
S
, Fernández-Pello
S
, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: the 2019 update
. Eur Urol
. 2019
;75
(5
):799
–810
. 3.
Thorstenson
A
, Bergman
M
, Scherman-Plogell
AH
, Hosseinnia
S
, Ljungberg
B
, Adolfsson
J
, et al. Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005–2010: a population-based study from the National Swedish Kidney Cancer Register
. Scand J Urol
. 2014
;48
(3
):231
–8
. 4.
Tahbaz
R
, Schmid
M
, Merseburger
AS
. Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition
. Curr Opin Urol
. 2018
;28
:62
–79
. 5.
Fisher
R
, Gore
M
, Larkin
J
. Current and future systemic treatments for renal cell carcinoma
. Semin Cancer Biol
. 2013
;23
(1
):38
–45
. 6.
Motzer
RJ
, Rini
BI
, Bukowski
RM
, Curti
BD
, George
DJ
, Hudes
GR
, et al. Sunitinib in patients with metastatic renal cell carcinoma
. JAMA
. 2006
;295
(21
):2516
–24
. 7.
Ko
JJ
, Xie
W
, Kroeger
N
, Lee
JL
, Rini
BI
, Knox
JJ
, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study
. Lancet Oncol
. 2015
;16
(3
):293
–300
. 8.
Motzer
RJ
, Escudier
B
, McDermott
DF
, George
S
, Hammers
HJ
, Srinivas
S
, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma
. N Engl J Med
. 2015
;373
(19
):1803
–13
. 9.
Zak
KM
, Kitel
R
, Przetocka
S
, Golik
P
, Guzik
K
, Musielak
B
, et al. Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1
. Structure
. 2015
;23
(12
):2341
–8
. 10.
Miao
X
, Xu
R
, Fan
B
, Chen
J
, Li
X
, Mao
W
, et al. PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin
. Sci Rep
. 2018
;8
(1
):1605
. 11.
Cha
JH
, Chan
LC
, Li
CW
, Hsu
JL
, Hung
MC
. Mechanisms controlling PD-L1 expression in cancer
. Mol Cell
. 2019
;76
(3
):359
–70
. 12.
Wherry
EJ
, Kurachi
M
. Molecular and cellular insights into T cell exhaustion
. Nat Rev Immunol
. 2015
;15
(8
):486
–99
. 13.
McDermott
DF
, Atkins
MB
. PD-1 as a potential target in cancer therapy
. Cancer Med
. 2013
;2
(5
):662
–73
. 14.
Hu
Z
, Ye
L
, Xing
Y
, Hu
J
, Xi
T
. Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice
. Sci Rep
. 2018
;8
(1
):217
. 15.
Caldwell
C
, Johnson
CE
, Balaji
VN
, Balaji
GA
, Hammer
RD
, Kannan
R
. Identification and validation of a PD-L1 binding peptide for determination of PDL1 expression in tumors
. Sci Rep
. 2017
;7
(1
):13682
. 16.
Iacovelli
R
, Nolè
F
, Verri
E
, Renne
G
, Paglino
C
, Santoni
M
, et al. Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis
. Target Oncol
. 2016
;11
(2
):143
–8
. 17.
Xu
F
, Xu
L
, Wang
Q
, An
G
, Feng
G
, Liu
F
. Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis
. Int J Clin Exp Med
. 2015
;8
(9
):14595
–603
.18.
Ning
XH
, Gong
YQ
, He
SM
, Li
T
, Wang
JY
, Peng
SH
, et al. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues
. Oncotarget
. 2017
;8
(2
):3355
–63
. 19.
Shin
SJ
, Jeon
YK
, Kim
PJ
, Cho
YM
, Koh
J
, Chung
DH
, et al. Clinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell aarcinoma: association with oncogenic proteins status
. Ann Surg Oncol
. 2016
;23
(2
):694
–702
. 20.
Parker
AS
, Leibovich
BC
, Lohse
CM
, Sheinin
Y
, Kuntz
SM
, Eckel-Passow
JE
, et al. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma
. Cancer
. 2009
;115
(10
):2092
–103
. 21.
Abbas
M
, Steffens
S
, Bellut
M
, Becker
JU
, Grosshennig
A
, Eggers
H
, et al. Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?
Med Oncol
. 2016
;33
(6
):59
. 22.
Hara
T
, Miyake
H
, Fujisawa
M
. Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
. Urol Oncol
. 2017
;35
(6
):363
–9
. 23.
Abbas
M
, Steffens
S
, Bellut
M
, Eggers
H
, Grosshennig
A
, Becker
JU
, et al. Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC)
. Med Oncol
. 2016
;33
(7
):80
. 24.
Choueiri
TK
, Fay
AP
, Gray
KP
, Callea
M
, Ho
TH
, Albiges
L
, et al. PD-L1 expression in nonclear-cell renal cell carcinoma
. Ann Oncol
. 2014
;25
(11
):2178
–84
. 25.
Shin
SJ
, Jeon
YK
, Cho
YM
, Lee
JL
, Chung
DH
, Park
JY
, et al. The association between PD-L1 expression and the clinical outcomes to vascular endothelial growth factor-targeted therapy in patients with metastatic clear cell renal cell carcinoma
. Oncologist
. 2015
;20
(11
):1253
–60
. 26.
Thompson
RH
, Kuntz
SM
, Leibovich
BC
, Dong
H
, Lohse
CM
, Webster
WS
, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up
. Cancer Res
. 2006
;66
(7
):3381
–5
. 27.
Soliman
H
, Khalil
F
, Antonia
S
. PD-L1 expression is increased in a subset of basal type breast cancer cells
. PloS One
. 2014
;9
(2
):e88557
. 28.
Velcheti
V
, Schalper
KA
, Carvajal
DE
, Anagnostou
VK
, Syrigos
KN
, Sznol
M
, et al. Programmed death ligand-1 expression in non-small cell lung cancer
. Lab Invest
. 2014
;94
(1
):107
–16
. 29.
Liu
Y
, Carlsson
R
, Ambjørn
M
, Hasan
M
, Badn
W
, Darabi
A
, et al. PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients
. J Neurosci
. 2013
;33
(35
):14231
–45
. 30.
Spranger
S
, Spaapen
RM
, Zha
Y
, Williams
J
, Meng
Y
, Ha
TT
, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells
. Sci Transl Med
. 2013
;5
(200
):200ra116
–200r
. 31.
Martin
AM
, Nirschl
TR
, Nirschl
CJ
, Francica
BJ
, Kochel
CM
, van Bokhoven
A
, et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
. Prostate Cancer Prostatic Dis
. 2015
;18
(4
):325
–32
. 32.
Thompson
RH
, Gillett
MD
, Cheville
JC
, Lohse
CM
, Dong
H
, Webster
WS
, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
. Proc Natl Acad Sci U S A
. 2004
;101
(49
):17174
–9
. 33.
Iwai
Y
, Ishida
M
, Tanaka
Y
, Okazaki
T
, Honjo
T
, Minato
N
. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
. Proc Natl Acad Sci U S A
. 2002
;99
(19
):12293
–7
. 34.
Lee
CH
, Motzer
RJ
. Immune checkpoint therapy in renal cell carcinoma
. Cancer J
. 2016
;22
(2
):92
–5
. 35.
McDermott
DF
, Sosman
JA
, Sznol
M
, Massard
C
, Gordon
MS
, Hamid
O
, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia atudy
. J Clin Oncol
. 2016
;34
(8
):833
–42
. 36.
Motzer
RJ
, Penkov
K
, Haanen
J
, Rini
B
, Albiges
L
, Campbell
MT
, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
. N Engl J Med
. 2019
;380
(12
):1103
–15
. 37.
Weng
YM
, Peng
M
, Hu
MX
, Yao
Y
, Song
QB
. Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis
. Onco Targets Ther
. 2018
;11
:7529
–42
. 38.
Pardoll
DM
. The blockade of immune checkpoints in cancer immunotherapy
. Nat Rev Cancer
. 2012
;12
(4
):252
–64
. 39.
Prado-Garcia
H
, Romero-Garcia
S
, Aguilar-Cazares
D
, Meneses-Flores
M
, Lopez-Gonzalez
JS
. Tumor-induced CD8+ T-cell dysfunction in lung cancer patients
. Clin Dev Immunol
. 2012
;2012
:741741
. 40.
Duraiswamy
J
, Freeman
GJ
, Coukos
G
. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer
. Cancer Res
. 2013
;73
(23
):6900
–12
. © 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
